Sens (SENS) Q4 2025: Eversense 365 Drives 103% U.S. Patient Growth as Commercial Control Shifts In-House
Sensonics’ full integration of sales and marketing, combined with the Eversense 365 launch, doubled U.S. patient starts and pushed margin above 50% for the first time. The company’s transition from partner-led to direct commercialization has reset its business model, positioning Sensonics for outsized growth and margin leverage in 2026 as European expansion and new product launches approach.
Summary
- Direct Commercial Control Unlocks Margin and Agility: In-house sales, marketing, and service now drive operational efficiency and patient growth.
- Eversense 365 and DTC Spend Fuel Patient Doubling: Strategic investments in direct-to-consumer and channel expansion sharply accelerated adoption.
- European Rollout and Pipeline Set Up 2026-2028 Growth: CE Mark approval and upcoming Gemini and Freedom launches extend multi-year runway.
Performance Analysis
Sensonics delivered a transformative year, with revenue surging and gross margin expanding as the company assumed full commercial responsibility for Eversense 365, its year-long continuous glucose monitor (CGM). The transition from Essentia Diabetes Care to a fully integrated in-house model eliminated revenue sharing and allowed Sensonics to recognize 100% of U.S. sales, directly aligning commercial execution with strategic priorities. U.S. revenue growth outpaced international, reflecting the initial domestic focus and the impact of direct-to-consumer (DTC) marketing, which more than doubled new patient starts and expanded the prescriber base by 80%.
Gross margin improvement, now above 50%, was driven by the shift to consignment sales and operational leverage from higher volumes and direct sales. However, operating expenses rose sharply as Sensonics absorbed the full cost structure of a commercial organization, with SG&A increases tied to DTC campaigns, headcount, and transition expenses. R&D spend declined as Eversense 365 clinical development wound down, but will ramp again with the pivotal Gemini trial. Cash reserves remain solid, supported by an expanded debt facility, but cash utilization is expected to rise in 2026 as the company invests in European expansion, salesforce buildout, and pipeline progress.
- Margin Expansion: Gross margin surpassed 50% on higher mix of direct and consignment sales, a key inflection from prior years’ 25% levels.
- Patient Growth Acceleration: U.S. patient starts grew 103%, with DTC spend and new partnerships fueling adoption and retention.
- Operating Leverage in Transition: SG&A rose as Sensonics took on Essentia’s commercial spend, but future efficiency gains are expected as revenue scales.
Seasonality remains a factor, with Q1 softness expected due to insurance resets, but full-year guidance implies continued momentum as European launches contribute to top-line growth.
Executive Commentary
"The biggest decision we made in 2025 was to transition all commercial activities from a sense of diabetes care back to Senseonics, removing a layer of complexity from our operations and providing us with a new level of control and agility to execute on our focus strategy."
Tim Goodenough, President and Chief Executive Officer
"We expect full-year 2026 global net revenue to be approximately 58 to 62 million, representing year-over-year growth of 65 to 76% as the company completes the transition of Eversense commercialization from Essentia and brings the entire sales and marketing infrastructure in-house."
Rick Sullivan, Chief Financial Officer
Strategic Positioning
1. Integrated Commercial Model
Sensonics’ shift to direct sales, marketing, and customer service eliminates partner friction and revenue sharing, giving the company end-to-end control over the Eversense 365 patient journey. This move streamlines operations, enables rapid response to market needs, and unlocks margin, setting a new baseline for financial performance and strategic agility.
2. DTC and Channel Strategy
Heavy investment in direct-to-consumer marketing, calibrated at $12-15 million annually, has proven highly effective at driving awareness, lead generation, and conversion. Sensonics will refine this approach in 2026, spreading spend more evenly to optimize cost per lead and maximize returns, while leveraging geographic targeting around its EonCare inserter network to enhance efficiency.
3. Eversense 365 and Product Pipeline
Eversense 365, a year-long implantable CGM, is now approved in both the U.S. and EU, providing a differentiated value proposition for both type 1 and type 2 diabetes patients. The product’s integration with Sequel’s Twist automated insulin delivery (AID) system expands its reach among pump users, while the upcoming Gemini and Freedom products promise further innovation with integrated batteries and direct-to-phone connectivity, targeting launches in 2027 and 2028.
4. European Expansion
CE Mark approval and the transition to direct sales in Europe position Sensonics to replicate its U.S. growth playbook. The company expects Europe to contribute roughly 20% of 2026 revenue, with the transition from Essentia expected to complete by mid-year and tenders rolling out through the fall.
5. Operational Leverage and Cost Structure
While SG&A and cash utilization are set to rise in 2026, management expects operating expenses to decline as a percentage of revenue over time. The company’s debt facility provides liquidity to fund expansion, and as the patient base and prescriber network scale, Sensonics anticipates improved efficiency and margin leverage.
Key Considerations
Sensonics is executing a high-stakes transition from a partner-dependent model to a fully integrated commercial organization, with implications for both growth and risk. The company’s ability to scale its salesforce, optimize DTC spend, and maintain high retention rates will be critical to sustaining its current momentum.
Key Considerations:
- Execution Risk in European Launch: Successful transition from Essentia and ramp-up of in-country teams is essential for capturing European CGM market share.
- DTC Efficiency and ROI: Spreading DTC spend more evenly and targeting high-return geographies will determine patient acquisition cost and growth sustainability.
- Inserter Network Scaling: Expansion of the EonCare nurse inserter network is directly tied to patient throughput and DTC effectiveness.
- Pipeline Progression: Timely completion and regulatory approval of Gemini and Freedom are necessary for multi-year growth and product differentiation.
- Margin and Cost Management: Maintaining gross margin above 50% and driving SG&A leverage as revenue scales will be central to long-term profitability.
Risks
Key risks include the operational complexity of transitioning commercial activities in Europe, potential delays or cost overruns in scaling the salesforce and inserter network, and execution risk in the Gemini and Freedom product launches. Seasonality and the high upfront cost structure could pressure cash flow if revenue ramps slower than anticipated, while competitive response from established CGM players remains an ongoing threat.
Forward Outlook
For Q1 2026, Sensonics anticipates a seasonal revenue dip due to insurance resets and higher patient assistance utilization. For full-year 2026, management guided to:
- Global net revenue of $58 to $62 million (65-76% YoY growth)
- Gross margin above 50%, improving sequentially
- Total operating expenses of $150 to $160 million, reflecting full in-house commercial costs and Gemini trial investment
Management expects 60% of revenue in the second half due to seasonality and renewal cycles, with European launches and Twist integration providing incremental upside.
- European rollout to complete by Q3, with tenders extending into fall
- Gemini pivotal trial to complete in 2026, with launch targeted for 2027
Takeaways
Sensonics’ transformation to a direct commercial model, combined with the differentiated Eversense 365 platform, has unlocked both top-line acceleration and margin leverage. The company’s ability to sustain rapid patient and prescriber growth while managing a much larger cost base will determine whether it can deliver on its ambitious multi-year outlook.
- Commercial Model Reset: The shift to in-house control is a structural change that enhances margin and strategic flexibility, but brings new execution risk.
- Growth Levers Aligned: DTC, channel expansion, and product innovation are working in concert, with early evidence of strong patient retention and expanding provider adoption.
- Watch European Execution: The pace and efficiency of the EU transition will be a key indicator of Sensonics’ ability to replicate U.S. success and scale globally.
Conclusion
Sensonics exits 2025 with a fundamentally stronger business model, robust patient growth, and a clear path to margin expansion. The transition to direct commercialization, pipeline progress, and European launch collectively set the stage for a pivotal 2026, but sustained execution will be required to capitalize on these opportunities.
Industry Read-Through
Sensonics’ experience highlights the strategic value of direct commercial control in medtech, particularly in high-growth, patient-driven markets like CGM. The company’s success with DTC marketing, channel optimization, and integrated care partnerships (such as AID system collaborations) will be closely watched by peers seeking to accelerate adoption and margin. For the broader diabetes technology sector, the Eversense 365 model and upcoming pipeline launches signal intensifying competition around sensor longevity, patient convenience, and seamless device integration, raising the bar for both established and emerging players.